The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
Simon K B SpohnAndrea FarolfiSarah SchandelerMarco M E VogelJuri RufMichael MixSimon KirsteFrancesco CeciStefano FantiHelena LanzafameFrancesca SeraniChristian GratzkeAugust SigleStephanie E CombsDenise BernhardtJuergen E GschwendJosef A BuchnerChristian TrappClaus BelkaPeter BartensteinLena UnterrainerMarcus UnterrainerMatthias EiberStephan G NekollaKilian SchillerAnca L GrosuNina-Sophie Schmidt-HegemannConstantinos ZamboglouJan C PeekenPublished in: European journal of nuclear medicine and molecular imaging (2022)
The non-invasive biomarker SUVmax can prognosticate outcome in patients undergoing sRT and recurrence confined to the prostatic fossa in PSMA-PET. Its addition might contribute to improve risk stratification of patients with recurrent PCa and to guide personalized treatment decisions in terms of treatment intensification or de-intensification. This article is part of the Topical Collection on Oncology-Genitourinary.